Last updated on February 2020

Observational Study to Evaluate Under Real-world Practice Conditions the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Digestive System Neoplasms | Liver Disorders | Neoplasm of unspecified nature of digestive system | LIVER DISEASE | HEPATIC NEOPLASM | Liver Cancer
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with confirmed diagnosis of unresectable HCC
  • Physician-initiated decision to treat with regorafenib (prior to study enrollment)

Exclusion Criteria:

  • Participation in an investigational program with interventions outside of routine clinical practice
  • Past treatment with regorafenib

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.